GlaxoSmithKline (GSK) Gets a Hold From Goldman Sachs
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk Plc
GSK Analyst Ratings
GlaxoSmithKline (GSK) Gets a Buy From Jefferies
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk Plc
Analysts Offer Insights on Healthcare Companies: Agilent (A), GlaxoSmithKline (GSK) and Stryker (SYK)
Analysts Have Conflicting Sentiments on These Healthcare Companies: EBOS Group Limited (AU:EBO), Craneware (GB:CRW) and GlaxoSmithKline (GB:GSK)
GSK Analyst Ratings
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk Plc
GSK Analyst Ratings
Jefferies Upgrades GSK to Buy, Raises Price Target to $48
GSK Analyst Ratings
Berenberg Bank Adjusts GSK Price Target to $41 From $44, Maintains Buy Rating
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk Plc
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk Plc
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk Plc
Analysts' Opinions Are Mixed on These Healthcare Stocks: Novartis AG (Six Swiss: CH:NOVN), CompuGroup Medical (GB:0MSD) and GlaxoSmithKline (GB:GSK)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amedisys (AMED), Atrys Health SA (Frankfurt: DE:A2T) and GlaxoSmithKline (GB:GSK)
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk Plc
RBC Downgrades BELLUS Health to Sector Perform From Outperform, Cuts Price Target to $14.75 From $21 Amid GSK Deal; Speculative Risk Kept